Cargando…
Managing pregnancy in inflammatory rheumatological diseases
Historically, pregnancy in women with many inflammatory rheumatic diseases was not considered safe and was discouraged. Combined care allows these pregnancies to be managed optimally, with the majority of outcomes being favorable. Disease activity at the time of conception and anti-phospholipid anti...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3157639/ https://www.ncbi.nlm.nih.gov/pubmed/21371350 http://dx.doi.org/10.1186/ar3227 |
_version_ | 1782210323475857408 |
---|---|
author | Jain, Varsha Gordon, Caroline |
author_facet | Jain, Varsha Gordon, Caroline |
author_sort | Jain, Varsha |
collection | PubMed |
description | Historically, pregnancy in women with many inflammatory rheumatic diseases was not considered safe and was discouraged. Combined care allows these pregnancies to be managed optimally, with the majority of outcomes being favorable. Disease activity at the time of conception and anti-phospholipid antibodies are responsible for most complications. Disease flares, pre-eclampsia, and thrombosis are the main maternal complications, whereas fetal loss and intrauterine growth restriction are the main fetal complications. Antirheumatic drugs used during pregnancy and lactation to control disease activity are corticosteroids, hydroxychloroquine, sulphasalzine, and azathioprine. Vaginal delivery is possible in most circumstances, with cesarean section being reserved for complications. |
format | Online Article Text |
id | pubmed-3157639 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-31576392011-08-25 Managing pregnancy in inflammatory rheumatological diseases Jain, Varsha Gordon, Caroline Arthritis Res Ther Review Historically, pregnancy in women with many inflammatory rheumatic diseases was not considered safe and was discouraged. Combined care allows these pregnancies to be managed optimally, with the majority of outcomes being favorable. Disease activity at the time of conception and anti-phospholipid antibodies are responsible for most complications. Disease flares, pre-eclampsia, and thrombosis are the main maternal complications, whereas fetal loss and intrauterine growth restriction are the main fetal complications. Antirheumatic drugs used during pregnancy and lactation to control disease activity are corticosteroids, hydroxychloroquine, sulphasalzine, and azathioprine. Vaginal delivery is possible in most circumstances, with cesarean section being reserved for complications. BioMed Central 2011 2011-02-25 /pmc/articles/PMC3157639/ /pubmed/21371350 http://dx.doi.org/10.1186/ar3227 Text en Copyright ©2011 BioMed Central Ltd |
spellingShingle | Review Jain, Varsha Gordon, Caroline Managing pregnancy in inflammatory rheumatological diseases |
title | Managing pregnancy in inflammatory rheumatological diseases |
title_full | Managing pregnancy in inflammatory rheumatological diseases |
title_fullStr | Managing pregnancy in inflammatory rheumatological diseases |
title_full_unstemmed | Managing pregnancy in inflammatory rheumatological diseases |
title_short | Managing pregnancy in inflammatory rheumatological diseases |
title_sort | managing pregnancy in inflammatory rheumatological diseases |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3157639/ https://www.ncbi.nlm.nih.gov/pubmed/21371350 http://dx.doi.org/10.1186/ar3227 |
work_keys_str_mv | AT jainvarsha managingpregnancyininflammatoryrheumatologicaldiseases AT gordoncaroline managingpregnancyininflammatoryrheumatologicaldiseases |